1[2] Yamamoto M,Sugahara K(1992). Overview of the general rules for the clinic and pathological study of primary liver cancer in Japan in Tobe T,Kameda H,Okudaira M,et al.eds. Primary liver cancer in Japan[M]. Tokyo:Springer-Verlag,1992.382～392． 被引量：1
2Garvey JS. Immunity and the red - blood cell[J]. Lancet, 1982, (1):223 - 227. 被引量：1
3Shan H, Gupta RK, Golub S H, et al. Identification of a natural killer enhancing factor(NKEF) from human erythroid cell [ J ]. Cell immunol,1993,147(1): 1 - 7. 被引量：1
4Sadallahg S, Giostro E, Mentha G, et al. increased level of soluble complement receptor in serum patients with liver disease[ J]. Hepatology,1996, 24(10) :118 - 122. 被引量：1
5Di Bona, Motalto G, Clemenza L, et al, soluble complement receptor type 1 (scr1) in cirrhosis liver disease:serum level at different stages of liver diseases[J]. Clin Exp Immunol, 1998, 114(1):102- 105. 被引量：1
6Inadn Y, Kaniyama M, K anemitsu T, et al. Invivobinding of circulating immune complexes by C3b receptors(CR1) of transfused erythrocytes[ J].Ann Rheum Dis, 1989, (48) :287 - 294. 被引量：1
7Siegel I, Liu TL, Gieicher N, et al. the red- cell immune system[J].Lancet, 1981,2(8246) :556 - 561. 被引量：1
8Woodruff E. Binding of model immune complexes to erythrocyte CR1 facilitates immune complexe up take by U937 cells [ J ]. J of imnunology,1989, (142) :4366 - 4371. 被引量：1
